| Company News |
Disclosures Under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Zydus Cadila
(August 23, 2010)
|
Cadila Health - Disclosures under Reg.13(4) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Zydus Cadila
(August 20, 2010)
|
U.S. District Court Rules Against Lilly Regarding Strattera Patent
Eli Lilly
(August 12, 2010)
|
Cadila Health - Outcome of AGM
Zydus Cadila
(August 03, 2010)
|
Cadila Health - Results Press Release
Zydus Cadila
(July 27, 2010)
|
Cadila Health - Announces Q1 results
Zydus Cadila
(July 27, 2010)
|
Zydus Cadila Q1 Net Profit Up by 60%
Zydus Cadila
(July 27, 2010)
|
Daily Market Movers (15 Jul 2010)
(July 16, 2010)
|
Zydus Wellness’ Net Profit up by 52.4% in Q1
Zydus Cadila
(July 16, 2010)
|
Shire Files Suit against Cadila Healthcare Limited, doing business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc
Cosmo Pharmaceuticals
(July 12, 2010)
|
|
|
|
|
EvaluatePharma® - the premier source for pharma and biotech analysis.
Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status, deals, license revenues and much more.
|
| Company Profile |
|
|
| Profile
|
Zydus Cadila, an India based pharmaceutical company that markets generic products worldwide. Zydus Cadila is the holding company for Cadila Healthcare. Has active pharmaceutical ingredients (API) business and is developing a pipeline of NMEs. |
| Listed or Private Company
|
Listed |
| Company Classification
|
Generic |
| Company Website
|
Website
|
|
Full Company Profile Information
| EventAnalyzer - Last Key Event |
|
| Closing Price DateClosing Price Date
|
EventAnalyzer Note
|
Market Cap (US $m)
|
Change (%)
|
Change (+$m)
|
| 7/15/2010 |
15 Jul: Company's competitor, Serum Institute, launches its nasal swine flu vaccine, Nasovac, at half the price of Zydus' VaxiFlu-S. |
2,944 |
-3.0% |
-91 |
|
| RX Sales Chart |
| Zydus Cadila
|
Data
|
Growth
|
|
2007 |
2008 |
2008 |
| Revenues By Segment
|
| Pharmaceuticals
|
| Pharmaceuticals Sales (In-depth)
|
| Rx & OTC Pharmaceuticals
|
| Prescription (Rx) Pharmaceuticals |
438 |
476 |
|
+9% |
|
|
| Therapy Area Focus in 2008 |
| Zydus Cadila
|
|
2008 |
| WW Rx & OTC Sales By Therapy Area
|
| Main Categories
|
| Other Rx & OTC Pharma |
476 |
|
| EvaluatePharma® Coverage of Marketed and Pipeline Products |
|
|
|
|